Eiger BioPharmaceuticals (NASDAQ:EIGR) Rating Lowered to Hold at Zacks Investment Research
Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly […]
Source: etfdailynews.com